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The role of the tumor microenvironment in leukemias and lymphomas is well established,
yet the intricacies of how the malignant cells regulate and influence their non-malignant
counterparts remain elusive. For example, chronic lymphocytic leukemia (CLL) is an
expansion of malignant CD5+CD19+ B cells, yet the non-malignant T cells play just as
large of a role in disease presentation and etiology. Herein, we review the dynamic tumor
cell to lymphoid repertoire interactions found in two non-Hodgkin’s lymphoma subtypes:
CLL and angioimmunoblastic T-cell lymphoma. We aim to highlight the pivot work done
in the murine models which recapitulate these diseases and explore the insights that can
be gained from studying the immuno-oncological regulation of non-malignant lymphoid
counterparts.
Keywords: lymphoma, chronic lymphocytic leukemia, angioimmunoblastic T-cell lymphoma, immune surveillance,
tumor-induced immunosuppression

INTRODUCTION
The cancer immunosurveillance and immunoediting concepts posit that the immune system plays
a protective role in tumor development through its ability to recognize and eradicate subclinical
tumors (1, 2). These theories suggest an ever-shifting balance of tumor eradication and tumor growth
wherein equilibrium can be lost and tumor growth can be promoted (3, 4). The promotion of tumor
growth can be viewed as a consequence of the immune system as a function of microenvironmental
interactions that have been shown to be vital for tumor development and survival (5). Therefore, with
the immune system playing seemingly two separate, yet opposite, roles within immuno-oncology
interactions it has garnered the “Janus-faced” moniker (3).
To understand the Janus-faced nature of tumor immunology is to understand the impact that a
growing tumor has upon its microenvironment; by which we mean how tumors regulate their nonmalignant counterparts. Perhaps it is not surprising the impact a tumor can have on the immune
system when one considers all the working parts of the immune system function that function in an
antitumor response (6). From NK cells lysing transformed clones, to presentation of tumor-associated
antigens by macrophages and dendritic cells to activate T- and therefore B-cells, the immune system
plays an integral role in producing and expanding tumor-specific responses (3).
Currently, the most effective method of studying the impact of a tumor microenvironment
(TME) on a host immune system is through the use of murine models (7). Specifically, this would
extend to transgenic murine models as they allow for the “natural” propagation of a clinical tumor
within an immunocompetent host; most closely mirroring what is found in humans. In this review,
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we summarize and discuss the impact two distinct hematological malignancies, chronic lymphocytic leukemia (CLL) and
angioimmunoblastic T-cell lymphoma (AITL), have upon their
adaptive immunological microenvironmental counterparts (i.e.,
T cells and B cells, respectively) (Figure 1). Explicitly, we summarize how murine models play a role in elucidating the impact
of a B-cell malignancy (i.e., CLL) on resident T cells, and the
impact of a T-cell malignancy (i.e., AITL) on resident B cells.
The aforementioned hematological malignancies were chosen as
representative malignancies to study immuno-oncological interactions due to their intense microenvironmental components. As
CLL is the most common adult leukemia, we are able rely on a
wealth of publications and data from both human and murine
investigations to summarize and discuss the above-mentioned
interactions. AITL on-the-other-hand is a much rarer and less
studied disease. Therefore, we will focus on what is currently
known concerning AITL immuno-oncological interactions and
put forward recommendations concerning AITL murine models
and directions for future investigations.

marrow stromal cells (BMSC) (11–13) or monocyte-derived
nurse-like cells (NLCs) (13). While both BMSC and NLCs display
similar recruitment of CLL cells through CXCL12–CXCR4 signaling (12–14), the mechanisms by which these compulsory stromal
cells engage in cross talk with CLL cells differ. In vitro, CLL cells are
attracted to BMSC and form a contact-dependent protective niche.
While in contact with the BMSC, the CLL cells undergo a processes
termed pseudoemperipolesis, which describes the migration of a
fraction of the CLL cells beneath the BMSC (14–16). This migration results in the cross talk and bi-directional activation of both
the BMSC and CLL cells leading to the upregulation of TCL1
and FOS/JUN in the CLL cells (17). Conversely, NLC-dependent
activation of CLL cells is characterized by enhanced CLL cell
viability through NF-κB activation and the BAFF-/APRIL-binding
pathways resulting in the expression of the anti-apoptotic protein
MCL-1 by CLL cells for prolonged survival (18). Additionally, CLL
cell activation through the B-cell receptor pathway is associated
with increased secretion of CCL3 and CCL4 chemokines, allowing
for the enhanced recruitment of accessory cells to the TME (19).
The progressive accumulation of CLL clones is primarily
attributed to increased apoptotic resistance via exploitation by the
above-described microenvironments (20); however, proliferative
centers of CLL have been identified (21). These proliferation centers, termed pseudo-follicles, are composed of Ki-67+, Survivin+,
p27−, Bcl-2+, CD23Hi CLL cells and CD40L+ T cells (21–24). As
a result, CD40 activation and IL-2/IL-10 signaling heighten CLL
proliferation and upregulate IRF4 (25).

CHRONIC LYMPHOCYTIC LEUKEMIA
Chronic lymphocytic leukemia is the most common adult
leukemia characterized by the clonal expansion of malignant
CD5+CD19+ B cells. The clinical presentation of CLL is heterogeneous, leading to both an indolent and aggressive form demarcated
by well-defined prognostic markers (i.e., IGVH status, CD38 and
ZAP70 expression, and chromosomal aberrations) (8–10).
Chronic lymphocytic leukemia is a malignancy highly dependent on its microenvironment illustrated by the fact that CLL cells
readily undergo apoptosis in vitro without coculture of bone

The Impact of CLL on T Cells

The T cells of CLL patients display distinct expression profiles (26) and are hallmarked by an exhausted phenotype,

Figure 1 | Summary of tumor–lymphoid interactions in chronic lymphocytic leukemia (CLL) and angioimmunoblastic T-cell lymphoma (AITL).
(A) CLL cell–resident T cell interactions exemplified by blockade of T-cell-mediated responses against the CLL cells. (B) AITL cell–resident B cell interactions
exemplified by stimulation of B cells resulting in hypergammaglobulinemia.
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attenuated immune synapse formation, decreased cytolitic activity,
migratory impairments, and dysregulated Rho-GTPase signaling.
T-cell exhaustion is defined by T cells displaying an overexpression of inhibitory receptors, decreased effector function, attenuated cytokine production, and decreased cytolitic
activity (27). CLL-T cells have been shown to upregulate the
surface expression of PD-1, CD160, and CD244, indicative of an
exhausted phenotype (28). Moreover, these markers are known
to be highly expressed on effector T cells, indicating a skewing of
the T-cell compartment of CLL patients to a more mature, effector differentiation, albeit with attenuated functionality. Further
support for a skewed T-cell compartment comes from CD4+
CLL-T cells having decreased gene expression of the JNK and
p38 MAPK pathway activators (MINK, NFRKB, PIK3CB) (26)
suggesting a defect in Th1 differentiation as the aforementioned
genes are crucial in the production of IFN-γ (29–31).
The immune synapse is a localization of receptors, costimulatory molecules, and adhesive anchors that allows for the engagement and recognition of antigen and activation by T cells (32).
During the activation process, the cytoskeleton of the T cell
undergoes intense rearrangements to better facilitate both contact and signaling through pseudopodia formation and cellular
polarization. In essence, the T cell grasps the antigen-presenting
cell (APC) forming what is called the immunological synapse
(33). Structurally, the immune synapse is described as possessing
three concentric rings called supramolecular activation clusters
(SMACs) (34). The central supramolecular activation cluster
houses the TCR molecules which are relocated from the periphery to be recycled, the peripheral SMAC is vital for maintaining
adhesion between the cells and is primarily composed of the
integrin, lymphocyte function-associated antigen 1 (LFA-1), and
the distal SMAC is a clustering of F-actin. The engagement of
the components of these SMACs influences the rearrangement of
the cytoskeleton both by signaling relayed via the TCRs and
through integrins such as LFA-1. For example, once LAT is phosphorylated via Zap70 following T-cell activation the Rho-family
GTPase exchange factor vav guanine nucleotide exchange factor 1
(Vav1) is recruited to the synapse (35, 36). Following Vav1 activation, the small GTPases Ras-related C3 botulinum toxin substrate
1 (Rac1) and cell division control protein 42 homolog (Cdc42)
bind GTP and activate actin nucleation promoting factors such
as Wiskott–Aldrich syndrome protein (WASp) and Wasp-family
verprolin-homologous protein 2 (WAVE2) which coordinate
actin-related protein 2/3 (Arp2/3)-dependent polymerization of
branched actin filaments (37–39). Following actin polymerization, the immunological synapse functions as a signal specifier
acting to focus TCR signaling responses to ensure efficient cross
talk with the bound APC. Dysregulation of the polymerization
processes could therefore lead to inefficient effector function
delivery through poor coordination of T-cell signaling or ineffectual delivery of signals to the APC.
Immune synapse formation, including both antigen presentation by CLL cells and the subsequent response by T cells, is
attenuated in CLL patients. Phenotypically, immune synapse malformation of CLL-T cells is displayed as a decrease in T-cell–APC
conjugation and F-actin polymerization, with further decrement
in T-cell receptor, WASp, Dynamin-2, Lck, Cdc42, and Filamin-A
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recruitment to the synapse site (40, 41). Additionally, the inhibitory receptors CD200R, CD272, and CD279 are upregulated in
CLL-T cells, and further impede immune synapse formation
(28, 42). These aforementioned defects also contribute to
decreased CD8+ T-cell cytolitic effector function, as granzyme B
is inefficiently packaged and localized to the immune synapse in
CLL CD8+ T cells (26, 28).
T cells from CLL patients display migratory defects through
LFA-1 directed T-cell motility (36). This defect is concurrent with
the previously described deficiency in cytoskeletal remodeling in
CLL-T cells (26) and has been determined to be dependent upon
LFA-1 conformation status. In terms of mRNA expression, there is
no difference in gene expression of LFA-1 between healthy T cells
and CLL-T cells. Rather, CLL-T cells showed impaired migration
due to the inefficiency of the low-affinity conformation of LFA-1
to bind intercellular adhesion molecule 1 causing an impediment
in leukocyte rolling, arrest, firm adhesion, and diapedesis (43).
At the center of CLL-mediated T-cell impairments is the
dysregulation of Rho-GTPase signaling in CLL-T cells. RhoGTPases are members of the Ras superfamily of small GTPbinding proteins and play key roles in T-cell development, T-cell
migration, and T-cell differentiation (44). This regulation is
carried out through Rho-GTPase-mediated cytoskeletal rearrangements, as well as signaling through numerous pathways
(45, 46). After coculture with CLL cells, T cells display lower active
GTPase signaling for RhoA, Rac1, and Cdc42, as compared with
coculture of T cells with healthy B cells (42). The dysregulation of
these signaling molecules is also tied to defective LFA-1-mediated
migration, where downregulated RhoA, Rac1, and potentiated
Cdc42 are noted among CLL-T cells. Importantly, Cdc42 levels
differed in CLL-T cell migration and stimulation assays and
suggest that CLL-T cells do not lose all Rho-GTPase signaling
potentials; however, they do not display identical signaling patterns as healthy T cells.

Evidence from the Eμ-TCL1 Model

T-cell impairment is a hallmark feature of CLL and is evident
within the Eμ-TCL1 murine model. Early investigations into
the T-cell phenotype in Eμ-TCL1 mice demonstrated decreased
antigen-specific activation, suppressed mitogen initiated proliferation, and impaired idiotype specific CD8+ T cell-mediated
CLL clone lysis (47). Gene expression profiling experiments supported the phenotypic differences, giving evidence to a dysregulation of the actin-cytoskeleton formation pathways, impaired
F-actin polymerization, and immune synapse formation (47).
Additionally, decreased expression of CD28, BTLA, Nfrkb, Pi3k,
Kfkb, Gadd45b, and Vav3 were observed.
Hofbauer and colleagues (48) were the first to report on the
immunophenotype of Eμ-TCL1 T-cells, finding an increase
in the absolute numbers of T cells in the peripheral blood of
leukemic mice, with the increased population consisting primarily of CD8+ T cells (~72%). Further, CLL-onset Eμ-TCL1 mice
experienced a shift between naïve and antigen experience T cells
(as assessed by CD44 expression), presenting with a 48:48 CD4+
naïve:experienced ratio, compared to a 80:20 ratio in wild-type
control mice. The CD8+ T cell ratio held a similar shift, with
an 86:14 naïve:experienced ratio in Eμ-TCL1 mice compared
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to a 70:27 ratio in wild-type controls (48). Importantly, this
investigation brought a unique insight into the pathogenesis of
CLL by establishing the engraftment of CLL spleenocytes within an
immunocompetent host. This adoptive transfer model decreased
the latency of CLL onset (83 days post-transfer compared to
247 days of Eμ-TCL1 development) and fully recapitulated the
abovementioned skewing of the T-cell compartment. These data
implicate the transferred CLL clones as being directly responsible
for the onset of disease progression and changes to the T-cell
compartment (48).
Recently, extensive work by the Gribben lab sought to delineate
the mechanism behind the PD-1/PD-L1 signaling axis in T cells
from Eμ-TCL1 mice, as well as provide important evidence for
use of PD-L1 checkpoint blockade therapy (49, 50). Importantly,
these studies lend microenvironmental data to the known role of
PD-1/PD-L1 signaling in human CLL (49). As CLL developed
in the Eμ-TCL1 mice, there was a significant correlation in the
reduction of the percentage of CD3+, CD3+CD4+ T cells, and an
expansion of CD3+CD8+ T cells in the spleen. This finding is in
agreement with Hofbauer et al. (48) of a decrease in the CD4+/
CD8+ ratio in Eμ-TCL1 mice for the spleen, peripheral blood,
and lymph node microenvironments. Further, CD3+CD8+
CD44−CD62L+ naïve cells were lost with CLL development, with
a shift toward CD44+ antigen-experienced T cells in the spleen,
peripheral blood, lymph node, and bone marrow microenvironments. These antigen-experienced CD44+ T cells held higher
proliferation indices, as evidenced by increased Ki-67+ ratios in
Eμ-TCL1 mice and adoptive transfer recipients (spleenocytes
transferred into 3-month Eμ-TCL1 mice).
Consistent with aging, both Eμ-TCL1 and wild-type mice
developed CD3+CD8+PD-1+ T cells, with higher absolute
numbers found in Eμ-TCL1 and adoptive transfer mice (49).
Investigation into the differential function of PD-1+ subsets in
Eμ-TCL1 mice revealed an enrichment within the PD-1+ population for cytotoxic cells (as assessed by CD107a+) with increased
proliferation ascribed to both PD-1high and PD-1low subsets, with
the PD-1high population having greater EdU incorporation compared to PD-1low. Finally, immune synapse assays indicated the
PD-1high population to form smaller synapses when compared to
the PD-1low population in Eμ-TCL1 T cells, suggesting the PD-1high
phenotype to contribute more toward T-cell impairment (49).
A causal role for the PD-1/PD-L1 signaling axis impairing
clone-specific immune responses in Eμ-TCL1 mice has been
supported by the work of both McClanahan and colleagues (50)
and Gassner et al. (51). α-PD-L1 blockade administered to EμTCL1 mice resulted in the effective control of CLL development,
concurrent with reduction in both spleen sizes and weights (50).
Treatment of adoptively transferred CLL tumor cells with either
recombinant PD-1 or anti-CD274 resulted in a significant reduction of transferred tumor cells at both 2- and 24-h time points
in peripheral blood (both time points), as well as in the spleen,
lymph nodes, and lungs (24-h time point) (51). Antibody blockade restored the relative median frequencies of CD3+, CD4+, and
CD8+ T cells, while normalizing the CD4+/CD8+ ratio (50). This
restoration was observed in conjunction with a reduced shift
toward the CD44+ phenotype seen in the peripheral blood, bone
marrow, and spleen.

Frontiers in Oncology | www.frontiersin.org

Angioimmunoblastic T-cell lymphoma is the second most
common subtype of mature T-cell lymphoma, known to originate
by the pathogenic clonal expansion of T-follicular helper (Tfh)
cells and concordant immune dysfunction (52, 53). AITL is an
aggressive disease, with a median survival <3 years post-diagnosis
and 10–30% of patients alive at 5 years post-diagnosis (54, 55).
The poor prognosis is partially due to the highly dysregulated
immune system of AITL patients, as most patients succumb to
infectious complications rather than the disease itself (54, 55).
The changes AITL imparts upon the lymph node microenvironment are considered a consequence of the cellular origins of the
disease. AITL patients display aberrant lymph node architecture,
including: hyperplasia of the follicular dendritic meshwork (53),
proliferation of high-endothelial venules, thickened extra follicular
meshworks, and neoplastic infiltrate (56). The neoplastic cells can be
medium sized with round, slightly irregular nuclei featuring abundant clear cytoplasm, with clustering around the high-endothelial
venules (57, 58). The neoplastic cells themselves may only account
for 5–30% of the tumor (59), and most of the clinical manifestations of the disease (i.e., lymphadenopathy, hepatosplenomegaly,
bone marrow involvement) represent complications arising from a
compromised immune system (60, 61).
As stated, the cell-of-origin for AITL is the Tfh cell. In healthy
conditions, these cells are formed from high affinity interactions
with B cells though a T-cell receptor:antigen-dependent manner
(62). Tfh cells are located within germinal centers and assist with
the production of high affinity antibodies by B cells, as well as
plasma cell differentiation, primarily through secretion of IL-21
and IL-4 (63, 64). These cells express high levels of ICOS and
CXCR5 and can be immunophenotypically described as CD4+,
CD8−, PD-1+, CD10+, BCL6+, and CXCL13+ cells (59, 65, 66).
As with many mature T-cell lymphomas, AITL cells also exhibit
defective expression of CD5 and CD7 (65), with further clonal
aberrations detected in ~90% of cases (58, 67–69). The gene
signature of AITL is described as very closely related to that
of Tfh cells, with upregulations of VEGF, PDGFRα, B-cell and
follicular dendritic cell genes, chemokines, extracellular matrix
components, and vascular biology-associated genes (70, 71).
Such findings are in accordance with the changes to the lymph
node architecture and the common involvement of B cells in
AITL disease progression.

The Impact of AITL on B-Cells

Due to a compromised immune system, in conjunction with
dysregulation of normal immune effector functions, there is a
high proclivity for developing secondary B-cell malignancies
among AITL patients (72). These secondary malignancies commonly present as either composite lymphomas of diffuse large
B-cell lymphoma + AITL (73, 74) or polyclonal populations
of immunoblasts or plasma cells (75, 76). The development of
these secondary malignancies suggests that the malignant T cells
still hold the effector capacity to stimulate B-cell proliferation
and antibody production and indicate a relationship between
the developments of the two separate disease phenotypes
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found the Tet2gt/gt T cells to be enriched for Tfh genes. Notable genes
found to be highly expressed in the Tet2gt/gt mice include: Bcl6,
cMaf, PD-1, Icos, and Cxcr5. Control CD4+ T cells were enriched
for genes involved in Th1/Th2 differentiation by comparison,
suggesting the downregulation of these genes is necessary for the
adoption of the Tfh phenotype. Sanger sequencing experiments
indicated that none of the concurrent mutations identified within
human AITL (e.g., Flt3, Npm1, Dmnt3a, Idh2, Rhoa) were found
in the Tet2gt/gt mice. Investigation into the differential methylation
patterns resulting from reduced Tet2 function revealed disruption
of the distribution of methylcytosine and hydroxymethylcytosine
in transcriptional start sites, gene body regions, and CpG islands.
Specifically, Bcl6 was identified as having aberrant methylation
suggesting this as a mechanism for increased Bcl6 expansion and
the induction of the outgrowth of Tfh-like cells (90).

(77, 78). Evidence supporting the above hypothesis includes:
development of hypergammaglobulinemia, gene signature analyses demonstrating an upregulation of genes for B-cell activation
and/or receptor signaling (CD22, CD20, CD21, CD23, CD24,
CD37) (79), and histological evaluation of germinal centers
displaying SH2D1A staining, a protein involved in bi-directional
activation of T and B cells (80).

Murine Models That Recapitulate the
Defining Characteristics of AITL

Unlike the Eμ-TCL1 mice for CLL, there is no current consensus
murine model for AITL. Currently, three genetic models most
faithfully recapitulate the defining disease characteristics of AITL
and how they impact resident B cells will be discussed below.

Tet2gt/gt Model of AITL

Heterozygous RoquinSan Model of AITL

The ten–eleven translocation 2 (TET2) gene has been found to
be mutated in multiple myeloid malignancies (81–83) as well as
a wide range of AITL and PTCL-NOS cases (84, 85). A loss of
function mutation in TET2 is associated with aberrant methylation processes involving the conversion of methylcytosine to
hydroxymethylcytosine, a common epigenetic marker in cancer
pathogenesis (86).
While previous studies of Tet2 mutations have been conducted
(87–89), Muto and colleagues were the first to describe the resultant disease in terms of its relation to the development of a T-cell
lymphoma with follicular helper T-cell-like features (90). After
backcrossing Tet2 gene trap mice onto the C57BL/6 background
and aging for 40–60 weeks, Tet2gt/gt mice had no differences in
complete blood counts or proportions of total T- or B-cell populations in comparison to wild-type or heterozygous controls. The
Tet2gt/gt mice presented with splenomegaly and preserved follicle
structures and an enlargement of germinal centers in some mice.
Flow cytometry analyses revealed an increase in the absolute #’s
of T- and B-cell populations, despite harboring no differences
in the proportions of the overall populations. Further analyses
displayed an increase in the proportions of Tfh populations in the
Tet2gt/gt mice, namely: CD4+CD44+PD-1+ and CD4+PD-1+Cxcr5+
Tfh cells.
In five of seven mice aged greater than 60 weeks (median age:
67 weeks), Muto and colleagues (90) observed the development
of increased splenomegaly, multiple swollen lymph nodes, and
liver and lung nodules in Tet2gt/gt mice. Histological analysis demonstrated the follicular structures of the spleen to be no longer
apparent due to the infiltration of large polymorphic cells with
irregular nuclei and characterized as CD4+PD-1+Cxcr5+ Tfh cells.
These T cells were determined to be clonal in nature, with distinct
rearrangements of TCR Vβ/Jβ2. Not observed histologically was
proliferation of high-endothelial venules, nor eosinophil infiltration. Then, >60-week mice presented with increased proportions
of CD4+ T-cell fractions and smaller B220+ B-cell fractions, with
the T-cell population mostly composed of CD44+PD-1+ cells. Of
note, there was no difference in serum Ig levels found in Tet2gt/gt
mice compared to controls.
Consistent with the observation that the malignant cells in
Tet2gt/gt mice were of Tfh origin, microarray analysis of isolated
splenic CD4+ T cells from Tet2gt/gt mice compared to control mice
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The sanroquin mouse strain bears a homozygous point mutation
in the Roquin/Rc3hl gene (91), designated as Roquinsan. This
point mutation results in increased binding affinity between
ROQUIN and Icos mRNA resulting in the decreased decay rate
of the transcript and overall upregulation of gene product (92).
The upregulation of Icos in these mice results in the expansion
of Tfh cells driving a disease progression equivocal to a systemic
lupus-like disease phenotype—a similar phenotype is observed
in Roquinsan/+ mice but in the absence of systemic autoimmunity (91). However, mice heterozygous for the Roquinsan allele
(Roquinsan/+) as described in Ellyard et al. (93) do not develop
systemic autoimmunity but instead present with asymmetric
lymphadenopathy. Roquinsan/+ mice had a complete absence
of generalized lymphadenopathy seen in homozygous mice by
8 weeks, but instead, 53% developed one to four enlarged lymph
nodes. The resultant lymphadenopathy was deemed non-lethal
and caused an increase in the cellularity of the affected lymph
nodes by 50- to 150-fold. A higher prevalence in females (65%)
compared to males (41%) was noted for the development of
the tumor-bearing lymph nodes. Histological examination of
tumor nodes in Roquinsan/+ mice demonstrated an effacement
of nodal architecture and vascularization, as well as infiltration
of small-to-medium sized T cells and large PAX5+ B cells, but no
expansion of the follicular dendritic cell network. An increase in
F4/80+ macrophages was observed with prominent vascularization and sinusoidal dilation. Reactive B blasts were observed in
interfollicular areas along with a proliferative and polymorphic
T-cell infiltrate, small clusters of mature plasma cells, and some
rosette formation between T cells and large blasts. Tumor lymph
nodes appeared to have no bearing on un-affected lymph nodes
in tumor-bearing Roquinsan/+ mice, as un-affected nodes displayed
typical morphologies with the exception of an increase in mature
plasma cells found within interfollicular areas. All Roquinsan/+ mice
presented with increased spleen weight compared to Roquin+/+
mice regardless of tumor incidence.
Concurrent with the highly affected lymph node environment of the Roquinsan/+ mice, increased serum IgG is observed
consistent with the development of hypergammaglobulinemia
at 15 weeks of age. While both Roquinsan/+ tumor-bearing and
non-tumor-bearing mice show a significant increase in IgG
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production compared to Roquin+/+ mice, tumor-bearing
Roquinsan/+ mice harbor an additional 1.5-fold increase above
non-tumor-bearing Roquinsan/+ mice. A finding further corroborated by flow cytometry analysis revealing an increased B-cell
fraction in the tumor-bearing lymph nodes of Roquinsan/+ mice
in comparison to normal lymph nodes from both Roquin+/+ and
Roquinsan/+ mice. Clonality assessments identified a clonal peak of
IgH in only 1 of 15 cases, in contrast to clonal arrangements in 12
of 15 cases for TCR-β.

the development of hypergammaglobulinemia. Igh and Tcrb
genes from spleens of primary lymphoma or SJL-diagnosed
mice were sequenced to assess the presence or absence of
clonal populations within the diseased mice. All sequenced
Tcrb clones contained identical V gene sequences, albeit with
different J gene sequences. For Igh sequences, high somatic
hypermutation was evident across all malignant samples with
overall identities <95%.

CONCLUSION

Swiss Jim Lambert (SJL) Model of AITL

Swiss Jim Lambert mice have been studied extensively as a
model of lymphoproliferative malignancies. In these mice,
the germinal center B cells express an endogenous mouse
mammary tumor virus (mtv-29) superantigen (vSAg) known
stimulate and activate CD4+ T cells which in turn drive B cell
proliferation (94, 95). Through this dual activation paradigm,
heterogeneous lymphoproliferative disorders develop in >90%
of mice (96). Recent studies have characterized the heterogeneity of SJL lymphomas finding similarities to non-Hodgkin
lymphomas and moving away from the classical reticulum cell
sarcoma diagnosis (97, 98).
Jain and colleagues (99) are the first to describe the similarities between RCS and AITL. In an analysis of 80 SJL mice, ~44%
developed classical SJL disease [i.e., Non-Hodgkin lymphoma
and/or reticulum cell sarcoma (100)]. In SJL disease-diagnosed
mice ranging from 2 to 24 months of age, flow cytometry demonstrated an expansion of Tfh cell frequencies (CD4+CXCR5+
ICOS+PD-1+) in the spleens of SJL mice compared to C57BL/6
controls. Additionally, increased frequencies of splenic GC B cells
(B220+FAS+GL-7+) were also found in SJL mice compared to
C57BL/6 controls. Microarray analysis of a time course of SJL
spleens (mice aged 6 weeks, 6 months, 12 months) revealed a
progressive upregulation of genes involved in Tfh signaling,
namely: Il21, Il10, Ccl8, and Ccl12. Knockout experiments
investigating the impact of IL-21-mediated signaling on the SJL
mice established that Il21r−/− SJL mice showed significant reductions in frequencies of total CD4+ T cells and Tfh cells in 9.5- to
12-month mice. A finding concurrent with reduced frequencies
of GC B cells seen in 3- to 12-month Il21r−/− SJL compared to
SJL WT controls (99). This finding verifies the IL-21 signaling as
the etiology of SJL-diseased mice, and re-affirms SJL disease as
Tfh-based as IL-21 is considered the major effector cytokine for
Tfh cells (101).
Diagnosed SJL-diseased mice underwent age-related changes
in splenic and lymph node architecture as assessed by peanut
agglutinin (PNA) reactivity. Younger mice had well preserved
follicular structures, but by 12 months had uniformly enlarged
structures with uneven PNA reactivity. Some mice were noted
as having highly enlarged follicles that did not contain germinal
centers. The uncontrolled expansion of these follicles leads to the
white pulp compressing the red pulp in the spleen.
Higher sera IgG2b protein levels were found in SJL mice
compared to C57BL/6 controls. Il21r−/− mice exhibited lower
sera IgG2b sera levels compared to wild-type SJL mice,
implicating the expanded Tfh cell population as a driver of

Frontiers in Oncology | www.frontiersin.org

The Eμ-TCL1 mouse is a powerful model for CLL with a highly
analogous microenvironment to that of the human disease (102).
Reviewed herein, we see the powerful effect a B-cell malignancy
can have on its T-cell counterparts. In CLL, there is a skewing
of the T-cell compartment toward antigen-experienced CD8+
cytotoxic T cells. These cells further express exhaustion markers
(e.g., PD-1) that demonstrate their inability to effectively control
malignant clones. In this scenario, we see that a tumor-specific
immune response has been stymied by the malignancy itself,
allowing for continued tumor growth and dissemination. Support
for this observation is seen in that adoption of the exhausted
and skewed T-cell phenotype is dependent on the presence of
CLL clones (48), and α-PD-1 blockade therapies are successful
in restoring the protective capability of the immune system
(50, 51). These results demonstrate the potential of treatments
aimed at restoring immune equilibrium to help combat tumors
in vivo and give further credence to the necessity and power of
murine models to support bench-to-bedside investigations.
While there is no current consensus murine model for AITL,
we have reviewed the three most prominent proposals to-date.
Of these, both the heterozygous Roquinsan and SJL models
appear most suited to be used in future studies modeling AITL
microenvironmental interactions. Importantly, both of these
models faithfully recapitulate defining disease characteristics
of AITL, including: Tfh expansion, hypergammaglobulinemia,
effacement of lymphoid architecture, clonal populations, and
increased high-endothelial vascularization. It stands to reason
that future investigations should be aimed not only at additional
model validations and Tfh-based characterization but also focus
on the B-cell involvement of AITL that could be key to disease
pathogenesis.
Taken together, both murine models for CLL and AITL
effectively recapitulate the in vivo expansion of key immune
cells. Studies on CLL that have included both cell types in their
investigations have provided exceptional clinical insight to
modulate immune competence and provide treatment for CLL
(including through immunomodulation therapy). Consequently,
as seen in CLL, therapies targeted at the lymphoid counterpart
of AITL (i.e., B cells) could hold high efficacy and aide in the
understanding of tumor microenvironmental manipulation of
resident B cells.
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